Education
About Us
Working with TipRanks
Follow Us
Endra Life Sciences (NDRA)
:NDRA
Total Valuation
ENDRA Life Sciences has a market cap or net worth of $2.07M. The enterprise value is $715.98K.
Market Cap$2.07M
Enterprise Value$715.98K
Share Statistics
ENDRA Life Sciences has 562.21K shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding562.21K
Owened by Insiders27.19%
Owened by Instutions
Financial Efficiency
ENDRA Life Sciences’s return on equity (ROE) is -1.78 and return on invested capital (ROIC) is -173.80%.
Return on Equity (ROE)-177.77%
Return on Assets (ROA)-148.95%
Return on Invested Capital (ROIC)-173.80%
Return on Capital Employed (ROCE)-179.81%
Revenue Per Employee$20,400.381
Profits Per Employee-$419,927.571
Employee Count21
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ENDRA Life Sciences is -3.33K. ENDRA Life Sciences’s PEG ratio is 44.02.
PE Ratio-3.33K
PS Ratio0.00
PB Ratio5.92K
Price to Fair Value5.92K
Price to FCF-3.50K
Price to Operating Cash Flow-3.51K
PEG Ratio44.02
Income Statement
In the last 12 months, ENDRA Life Sciences had revenue of $428.41K and earned -$8.82M in profits. Earnings per share was -$10.15.
Revenue$428.41K
Gross Profit$261.36K
Operating Income-$7.98M
Pretax Income-$8.82M
Net Income-$8.82M
EBITDA-7.79M
Earnings Per Share (EPS)-10.15
Cash Flow
In the last 12 months, operating cash flow was -$8.06M and capital expenditures -$22.88K, giving a free cash flow of -$8.08M billion.
Operating Cash Flow-$8.06M
Free Cash Flow-$8.08M
Free Cash Flow per Share-$14.38
Dividends & Yields
ENDRA Life Sciences pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-0.03%
Earnings Yield-0.03%
Stock Price Statistics
Beta0.43
52-Week Price Change-99.20%
50-Day Moving Average4.32
200-Day Moving Average31.18
Relative Strength Index (RSI)42.79
Average Volume (3m)59.40K
Important Dates
ENDRA Life Sciences upcoming earnings date is May 19, 2025, TBA.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
ENDRA Life Sciences as a current ratio of 3.36, with Debt / Equity ratio of 0.07
Current Ratio3.36
Quick Ratio3.36
Debt to Market Cap<0.01
Net Debt to EBITDA0.25
Interest Coverage Ratio0.00
Taxes
In the past 12 months, ENDRA Life Sciences has paid $7.00 in taxes.
Income Tax$7.00
Effective Tax Rate0.00%
Enterprise Valuation
ENDRA Life Sciences EV to EBITDA ratio is -3.43K, with an EV/FCF ratio of -3.50K.
EV to Sales0.00
EV to EBITDA-3.43K
EV to Free Cash Flow-3.50K
EV to Operating Cash Flow-3.51K
Balance Sheet
ENDRA Life Sciences has $4.75M in cash and marketable securities with $237.16K in debt, giving a net cash position of -$4.51M billion.
Cash & Marketable Securities$4.75M
Total Debt$237.16K
Net Cash-$4.51M
Net Cash Per Share-$8.02
Tangible Book Value Per Share$0.63
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ENDRA Life Sciences is $75.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$75.00
Price Target Upside1938.04%
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast71.89%